TT Electronics Minneapolis Facility Secures FDA Registration

TT Electronics, a global provider of engineered technologies for performance critical applications, today announced the receipt of U.S. Federal Drug Administration (FDA) registration for its Minneapolis, Minnesota manufacturing facility. Securing this registration allows the company to manufacture finished instruments and devices such as imaging, diagnostic and therapeutic equipment for the healthcare market, in the USA.

Now as an FDA registered location, the facility is recognised by and subject to the rigorous standards of the FDA, further reinforcing the company’s commitment to supporting its global customers with a wide range of high-reliability products and services across key highly regulated end markets. This development also builds on FDA registration received last year by the TT Cleveland facility which has paved the way for increasing collaboration between the two locations to further support our medical customers with complete, vertically integrated solutions by utilising the complimentary capabilities of our teams and sites in Ohio and Minnesota respectively. These registrations and this enhanced value offering further demonstrate the steps TT is actively taking to better respond to the increased demand seen in the medical and life science domain.

“This latest milestone demonstrates our commitment to the healthcare industry and the momentum behind our growth strategy. FDA designation is not easily awarded and will provide a significant advantage in supporting our current customer base, many of whom are global leaders in their fields. TT has long been a partner for medical device and life science technology innovators and we’re proud to continue securing milestones like this one to support our customers with an enhanced ability to leverage our growing capabilities in the USA. Our increasing expertise and track record in manufacturing and delivering finished, complex medical products – still founded on world-class service is a compelling offering which we’re delighted to provide to our partners,” said TT Electronics Power Solutions VP/GM, Matt Sweaney.

Manufacturing facilities involved in the production and distribution of medical devices intended for use in the United States healthcare sector are required to register annually with the FDA. This registration provides the FDA with the location of medical device establishments and the devices manufactured at those establishments. Knowing where devices are made increases the nation’s ability to prepare for and respond to public health emergencies such as those experienced in recent years in responding to the coronavirus pandemic.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy